16-186 - Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Status: open

A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer

Treatment for Cervical Cancer

Contact Us Or call (251) 445-9834


The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation. IRB Number 16-186


This trial is sponsored by Merck.

Providers Associated With This Trial

Principle Investigator

    Sub Investigators

    • Rocconi RodneyView Profile
      Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistInterim Director of Mitchell Cancer Institute; Associate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
    This link will open in a new tab or window.